.
despite neutral imaging results, adalimumab did improve other key markers of inflammation in the blood including glyca, crp, tnf, and il-6.
.
of the life claims declined, 0.85 per cent were due to mis-representation and 0.16 per cent due to the definition of terminal illness not being met.
.
. (image: rex/shutterstock)
.
.
.